Sanara MedTech Inc. Announces Changes to Its Board of Directors
07 Octobre 2024 - 3:15PM
Sanara MedTech Inc. -- Based in Fort Worth, Texas, Sanara MedTech
Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a medical
technology company focused on improving clinical outcomes and
reducing healthcare expenditures in the surgical, chronic wound and
skincare markets announced today changes to its Board of Directors
(“Board”). After a long tenure of service with the predecessor
company and Sanara, Mr. James “Jim” Stuckert has resigned from his
position as a director, and Mr. Keith Myers has been appointed to
serve as a director on the Board in order to fill the vacancy
resulting from Mr. Stuckert’s resignation. Mr. Stuckert will
continue to serve the Board as Director Emeritus.
Ron Nixon, Sanara’s Executive Chairman and CEO,
stated, “I want to thank Jim for his leadership and extensive
contributions over the past many years of Sanara’s growth. I speak
for the entire board in thanking him for his contributions to the
Company and wishing him the best.” Mr. Nixon added, “I have known
Keith Myers for decades while he led the LHC Group team to become
one of the most impactful home health and hospice providers in the
U.S. His leadership, strategic vision, and experience will be
invaluable as Sanara enters its next phase of growth.”
Mr. Myers is the chairman and CEO emeritus of
LHC Group, one of the largest and highest quality in-home
healthcare providers in the United States. He co-founded LHC Group
in 1994 and led its growth from a single freestanding home health
agency in rural Louisiana to a publicly traded company with 29,000
employees and 950 agency locations across 38 states and the
District of Columbia.
As a visionary and influential leader in the
home health industry, Mr. Myers has contributed to shaping the
policy and practice of in-home care delivery in the United States.
He is the current chairman and a co-founder of the Partnership for
Quality Home Healthcare, a coalition of home health providers
dedicated to improving the program integrity, quality, and
efficiency of home healthcare. He has also served on technical
expert panels, prepared research and white papers, and participated
in data analysis and presentations to advise the Centers for
Medicare & Medicaid Services and other key policymakers.
Mr. Myers is a recipient of multiple national
awards and honors, including the National Entrepreneur of the Year
in the field of healthcare services and induction into the National
Home Care & Hospice Hall of Fame.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology
company focused on developing and commercializing transformative
technologies to improve clinical outcomes and reduce healthcare
expenditures in the surgical, chronic wound and skincare markets.
The Company markets, distributes and develops surgical, wound and
skincare products for use by physicians and clinicians in
hospitals, clinics and all post-acute care settings and offers
wound care and dermatology virtual consultation services via
telemedicine. Sanara’s products are primarily sold in the North
American advanced wound care and surgical tissue repair markets.
Sanara markets and distributes CellerateRX® Surgical Activated
Collagen, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE®
Extracellular Matrix as well as a portfolio of advanced biologic
products focusing on ACTIGEN™ Verified Inductive Bone Matrix,
ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive
Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and
BIASURGE® Advanced Surgical Solution to the surgical market. In
addition, the following products are sold in the wound care market:
BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS®
Antimicrobial Wound Gel, and BIAKŌS® Antimicrobial Skin and Wound
Irrigation Solution. Sanara’s pipeline also contains potentially
transformative product candidates for mitigation of opportunistic
pathogens and biofilm, wound re-epithelialization and closure,
necrotic tissue debridement and cell compatible substrates. The
Company believes it has the ability to drive its pipeline from
concept to preclinical and clinical development while meeting
quality and regulatory requirements. Sanara is constantly seeking
long-term strategic partnerships with a focus on products that
improve outcomes at a lower overall cost.
Information about Forward-Looking
Statements
The statements in this press release that do not
constitute historical facts are “forward-looking statements,”
within the meaning of and subject to the safe harbor created by the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by terms such as “aims,” “anticipates,”
“believes,” contemplates,” “continue,” “could,” “estimates,”
“expect,” “forecast,” “guidance,” “intend,” “may,” “plan,”
“possible,” “potential,” “predicts,” “preliminary,” “projects,”
“seeks,” “should,” “targets,” “will” or “would,” or the negatives
of these terms, variations of these terms or other similar
expressions. These forward-looking statements include, among
others, statements regarding the Company’s future growth. These
items involve risks, contingencies and uncertainties such as the
extent of product demand, market and customer acceptance of the
Company’s products, the effect of economic conditions, competition,
pricing, uncertainties associated with the development and process
for obtaining regulatory approval for new products, the ability to
consummate and integrate acquisitions, and other risks,
contingencies and uncertainties detailed in the Company’s SEC
filings, which could cause the Company’s actual operating results,
performance or business plans or prospects to differ materially
from those expressed in, or implied by these statements.
All forward-looking statements speak only as of
the date on which they are made, and the Company undertakes no
obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events, except as
required by applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor
Relations713-826-0524CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.
Sanara MedTech (NASDAQ:SMTI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Sanara MedTech (NASDAQ:SMTI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024